These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Evidence against a role for platelet-activating factor in hypoxic pulmonary vasoconstriction in the rat. McCormack DG; Barnes PJ; Evans TW Clin Sci (Lond); 1989 Oct; 77(4):439-43. PubMed ID: 2805602 [TBL] [Abstract][Full Text] [Related]
25. Rate of NO scavenging alters effects of recombinant hemoglobin solutions on pulmonary vasoreactivity. Resta TC; Walker BR; Eichinger MR; Doyle MP J Appl Physiol (1985); 2002 Oct; 93(4):1327-36. PubMed ID: 12235032 [TBL] [Abstract][Full Text] [Related]
27. Role of thromboxane in mediating the intrarenal vasoconstriction induced by unmodified stroma free hemoglobin in the isolated perfused rat kidney. Lieberthal W; LaRaia J; Valeri CR Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):663-7. PubMed ID: 1391492 [TBL] [Abstract][Full Text] [Related]
28. Involvement of platelet-activating factor in the modulation of vascular tone in the isolated perfused rabbit kidney. Cailleaux S; Lopes-Martins RA; Aimbire F; Cordeiro RS; Tibiriçá E Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):505-11. PubMed ID: 10431763 [TBL] [Abstract][Full Text] [Related]
29. Platelet-activating factor is a key mediator of pulmonary vasoconstriction and bronchoconstriction after antigen challenge in the perfused sensitized rabbit lung. Shouji K; Enzan K; Mitsuhata H; Yoshioka N Shock; 1998 Jun; 9(6):412-5. PubMed ID: 9645492 [TBL] [Abstract][Full Text] [Related]
31. Role of circulating blood components and thromboxane in anaphylactic vasoconstriction in isolated canine lungs. Miyahara T; Shibamoto T; Wang HG; Koyama S J Appl Physiol (1985); 1997 Nov; 83(5):1508-16. PubMed ID: 9375313 [TBL] [Abstract][Full Text] [Related]
32. Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs. Pretolani M; Lefort J; Malanchère E; Vargaftig BB Eur J Pharmacol; 1987 Aug; 140(3):311-21. PubMed ID: 3653247 [TBL] [Abstract][Full Text] [Related]
33. Platelet-activating factor potentiates protamine-induced lung edema. Role of eicosanoids. Chen CR; Voelkel NF; Chang SW Am J Respir Crit Care Med; 1994 Jan; 149(1):34-40. PubMed ID: 8111595 [TBL] [Abstract][Full Text] [Related]
35. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Rabinovici R; Rudolph AS; Yue TL; Feuerstein G Circ Shock; 1990 Aug; 31(4):431-45. PubMed ID: 2397568 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of PAF-induced histamine secretion and bronchoconstriction by WEB 2086. Chand N; Pillar J; Nolan K; Diamantis W; Sofia RD Res Commun Chem Pathol Pharmacol; 1990 Jan; 67(1):155-8. PubMed ID: 1691522 [TBL] [Abstract][Full Text] [Related]
37. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation. Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485 [TBL] [Abstract][Full Text] [Related]
38. Effects of the PAF antagonist WEB 2086 on PAF-induced physiologic alterations and on IgE anaphylaxis in the rabbit. Lohman I; Halonen M Am Rev Respir Dis; 1990 Aug; 142(2):390-7. PubMed ID: 2382903 [TBL] [Abstract][Full Text] [Related]
39. Modulation of antigen- and ischemia-induced effects by the platelet-activating factor antagonist WEB-2086 in isolated sensitized rat hearts. Vleeming W; Wemer J; Porsius AJ J Cardiovasc Pharmacol; 1992; 20(5):790-9. PubMed ID: 1280743 [TBL] [Abstract][Full Text] [Related]